Allogene Therapeutics (ALLO) Competitors

Immunome (NASDAQ:IMNM) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Which has more volatility and risk, IMNM or ALLO?

Immunome has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.

Does the media prefer IMNM or ALLO?

In the previous week, Immunome had 9 more articles in the media than Allogene Therapeutics. MarketBeat recorded 23 mentions for Immunome and 14 mentions for Allogene Therapeutics. Immunome's average media sentiment score of 0.52 beat Allogene Therapeutics' score of 0.48 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has stronger earnings and valuation, IMNM or ALLO?

Allogene Therapeutics has lower revenue, but higher earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$9.04M	95.71	-$292.96M	-$3.08	-3.23
Allogene Therapeutics	$20K	11,702.06	-$257.59M	-$1.23	-0.87

Do analysts rate IMNM or ALLO?

Immunome presently has a consensus price target of $23.14, suggesting a potential upside of 132.83%. Allogene Therapeutics has a consensus price target of $8.44, suggesting a potential upside of 689.20%. Given Allogene Therapeutics' higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Allogene Therapeutics	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Is IMNM or ALLO more profitable?

Allogene Therapeutics has a net margin of 0.00% compared to Immunome's net margin of -1,687.08%. Allogene Therapeutics' return on equity of -53.37% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	-1,687.08%	-76.10%	-65.14%
Allogene Therapeutics	N/A	-53.37%	-41.23%

Do institutionals & insiders hold more shares of IMNM or ALLO?

44.6% of Immunome shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 7.7% of Immunome shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Allogene Therapeutics beats Immunome on 11 of the 16 factors compared between the two stocks.